No Data
Bide Pharmaceutical (688073): Profitability continues to improve with steady revenue growth.
Event: In the first three quarters of 2024, revenue reached 0.811 billion yuan (+0.79% year-on-year), net income attributable to parent company was 83.8539 million yuan (-26.05% year-on-year), non-net income attributable to parent company was 72.3904 million yuan.
Bide Pharmaceutical (688073): Structural adjustment, obvious elasticity, moving out of the low point of profitability.
Investment Highlights Performance: Revenue growth rate slowed down, profit growth rate rebounded in 2024Q1-3, achieving revenue of 0.811 billion yuan, yoy +0.79%; achieving net income attributable to parent company of 0.084 billion yuan, yoy -26.05%.
Bide Pharmaceuticals: third quarter report 2024
Third Quarter Report 2024
Bede Pharmaceuticals (688073.SH) released its performance for the first three quarters, with a net income of 83.85 million yuan, a year-on-year decrease of 26.05%.
Bide Pharmaceutical (688073.SH) disclosed its third quarter report for 2024. During the reporting period, the company achieved revenue of 8.1...
BiDe Pharmaceutical (688073.SH): The net income in the first three quarters was 83.8539 million yuan, a year-on-year decrease of 26.05%.
Gelonghui October 23rd丨Bide Pharmaceutical (688073.SH) announced that the company's revenue for the first three quarters was 0.811 billion yuan, a year-on-year increase of 0.79%; the net income attributable to the shareholders of the listed company was 83.8539 million yuan, a year-on-year decrease of 26.05%; the net income attributable to the shareholders of the listed company excluding non-recurring gains and losses was 72.3904 million yuan, a year-on-year decrease of 40.18%; basic earnings per share was 0.94 yuan.
No Data
No Data